Ann: Kazia's paxalisib obtains Rare Pediatric Disease Designation, page-82

I valued the Priority Review Voucher (PRV) at between AU$200m and $250m, it depends on availability at the time of sale, and how long after the cut off date 30 September 2020 it is sold.
Agreed, positive interim data from St Jude's DIPG trial, should be enough for management to submit a priority review application to the FDA for Paxalisib's approval for DIPG.

St Jude Children's Research Hospital is a participating site for the Pacific Pediatric Neuro-Oncology Consortium, which is funding Dr Matt Dun's DIPG trial early 2021, they will continue to collaborate and share DIPG research data.

https://www.pnoc.us/participating-sites/st-jude-childrens-research-hospital

Regards.